ArticleBiomaterials2014
Alveolar epithelial differentiation of human induced pluripotent stem cells in a rotating bioreactor.
Article in Biomaterials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- A Barrier to Defend - Models of Pulmonary Barrier to Study Acute Inflammatory Diseases.Frontiers in immunology · 2022Pooled it
- Current strategies and opportunities to manufacture cells for modeling human lungs.Advanced drug delivery reviews · 2020Pooled it
- NAMs for closing knowledge gaps in assessment of respiratory uptake - a PARC project.Frontiers in toxicology · 2026Article
- MHC class II of different non-professional antigen-presenting cells mediate multiple effects of crosstalk with CD4Frontiers in medicine · 2025Review
- Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.Stem cell research & therapy · 2024Review
- Bioengineering and Clinical Translation of Human Lung and its Components.Advanced biology · 2023Review
- Differentiation of human induced pluripotent stem cells into functional lung alveolar epithelial cells in 3D dynamic culture.Frontiers in bioengineering and biotechnology · 2023Article
- Lung-on-a-Chip Models of the Lung Parenchyma.Advances in experimental medicine and biology · 2023Article
- Stem cell-based therapy for pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Emerging Paradigms in Bioengineering the Lungs.Bioengineering (Basel, Switzerland) · 2022Review
- Differentiation of Human Induced Pluripotent Stem Cells into Definitive Endoderm Using Simple Dialysis Culture Device.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Bioengineering lungs: An overview of current methods, requirements, and challenges for constructing scaffolds.Frontiers in bioengineering and biotechnology · 2022Review
- Guided Self-Assembly of ES-Derived Lung Progenitors into Biomimetic Tube Structures That Impact Cell Differentiation.Bioengineering (Basel, Switzerland) · 2021Article
- 3D printed hydrogels with oxidized cellulose nanofibers and silk fibroin for the proliferation of lung epithelial stem cells.Cellulose (London, England) · 2021Article
- A Two-Step Bioreactor for Decellularized Lung Epithelialization.Cells, tissues, organs · 2021Article
- Stem cells and lung regeneration.American journal of physiology. Cell physiology · 2020Review
- Induced pluripotent stem cell-derived lung alveolar epithelial type II cells reduce damage in bleomycin-induced lung fibrosis.Stem cell research & therapy · 2020Article
- In vitro modelling of alveolar repair at the air-liquid interface using alveolar epithelial cells derived from human induced pluripotent stem cells.Scientific reports · 2020Article
- Efficient Differentiation of Mouse Induced Pluripotent Stem Cells into Alveolar Epithelium Type II with a BRD4 Inhibitor.Stem cells international · 2019Article
- A basic study on self-reconstitution of alveolar epithelium-like cells by tissue stem cells in mouse lung.In vitro cellular & developmental biology. Animal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Traditional stem cell differentiation protocols make use of a variety of cytokines including growth factors (GFs) and inhibitors in an effort to provide appropriate signals for tissue specific differentiation. In this study, iPSC-derived type II pneumocytes (iPSC-ATII) as well as native isolated human type II pneumocytes (hATII) were differentiated toward a type I phenotype using a unique air-liquid interface (ALI) system that relies on a rotating apparatus that mimics in vivo respiratory conditions. A relatively homogenous population of alveolar type II-like cells from iPSC was first generated (iPSC-ATII cells), which had phenotypic properties similar to mature human alveolar type II cells. iPSC-ATII cells were then cultured in a specially designed rotating culture apparatus. The effectiveness of the ALI bioreactor was compared with the effectiveness of small molecule-based differentiation of type II pneumocytes toward type 1 pneumocytes. The dynamics of differentiation were examined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), flow cytometry and immunocytochemistry. iPSC-ATII and hATII cells cultured in the ALI bioreactor had higher levels of type I markers, including aquaporin-5(AQ5), caveolin-1, and T1α, at both the RNA and protein levels as compared with the flask-grown iPSC-ATII and hATII that had been treated with small molecules to induce differentiation. In summary, this study demonstrates that a rotating bioreactor culture system that provides an air-liquid interface is a potent inducer of type I epithelial differentiation for both iPS-ATII cells and hATII cells, and provides a method for large-scale production of alveolar epithelium for tissue engineering and drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.